SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-19-000020
Filing Date
2019-11-05
Accepted
2019-11-05 16:02:47
Documents
63
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20190930x10qq319.htm 10-Q 1376586
2 EXHIBIT 10.1 allo-20190930xex101.htm EX-10.1 39881
3 EXHIBIT 31.1 allo-20190930xex311.htm EX-31.1 11055
4 EXHIBIT 31.2 allo-20190930xex312.htm EX-31.2 11082
5 EXHIBIT 32.1 allo-20190930xex321.htm EX-32.1 9516
12 exhibit101image1.jpg GRAPHIC 730366
  Complete submission text file 0001737287-19-000020.txt   6719390

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT allo-20190930.xml EX-101.INS 1034997
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20190930.xsd EX-101.SCH 45541
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20190930_cal.xml EX-101.CAL 67265
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20190930_def.xml EX-101.DEF 201246
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20190930_lab.xml EX-101.LAB 613076
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20190930_pre.xml EX-101.PRE 345462
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 191193224
SIC: 2836 Biological Products, (No Diagnostic Substances)